
    
      This is a phase II single arm study looking at the efficacy of 12 weeks of neoadjuvant
      apalutamide (ARN 509), combined with standard-of-care radical prostatectomy, for D'Amico
      intermediate to high risk prostate cancer patients. The phases of the study will include:
      screening, treatment and follow-up phases.

      Safety will be monitored throughout the study.
    
  